Table 5.
The correlations between PD1/PDL1 expression and CD68+M cells density at different locations in MSI and MSS GC
| MSI-CD68 | MSS-CD68 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor center (%) | Invasive front (%) | Tumor center (%) | Invasive front (%) | |||||||||||||
| Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | |
| PD1 | 1.000 | 0.051 | 0.708 | 0.292 | ||||||||||||
| Negative | 4(40) | 15(44) | 19 | 7(70) | 12(35) | 19 | 51(55) | 33(52) | 84 | 52(58) | 32(49) | 84 | ||||
| Positive | 6(60) | 19(56) | 25 | 3(30) | 22(65) | 25 | 41(45) | 30(48) | 71 | 38(42) | 33(51) | 71 | ||||
| Sum | 10(100) | 34(100) | 44 | 10(100) | 34(100) | 44 | 92(100) | 63(100) | 155 | 90(100) | 65(100) | 155 | ||||
| PDL1[T] | 0.361 | 0.361 | 0.102 | 0.290 | ||||||||||||
| Negative | 8(80) | 22(65) | 30 | 8(80) | 22(65) | 30 | 74(82) | 44(71) | 118 | 71(81) | 47(73) | 118 | ||||
| Positive | 2(20) | 12(35) | 14 | 2(20) | 12(35) | 14 | 16(18) | 18(29) | 34 | 17(19) | 17(27) | 34 | ||||
| Sum | 10(100) | 34(100) | 44 | 10(100) | 34(100) | 44 | 90(100) | 62(100) | 152 | 88(100) | 64(100) | 152 | ||||
| PDL1 | 0.743 | 0.147 | 0.001 | 0.014 | ||||||||||||
| Negative | 5(50) | 15(44) | 20 | 7(70) | 13(38) | 20 | 64(71) | 27(44) | 91 | 60(68) | 31(48) | 91 | ||||
| Positive | 5(50) | 19(56) | 24 | 3(30) | 21(62) | 24 | 26(29) | 35(56) | 61 | 28(32) | 33(52) | 61 | ||||
| Sum | 10(100) | 34(100) | 44 | 10(100) | 34(100) | 44 | 90(100) | 62(100) | 152 | 88(100) | 64(100) | 152 | ||||
GC: gastric cancer; MSI: microsatellite unstable; MSS: microsatellite stable; CD68+ M: CD68+ macrophage; PD1: programmed cell death protein 1; PDL1, programmed death ligand 1; In all 215 cases of gastric cancer, 199 cases immunohistochemical sections were evaluable for PD1 and CD68 simultaneously in tumor center and invasive front, 196 cases for PDL1 [T]/PDL1 and CD68 simultaneously in tumor center and invasive front.